These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33364965)

  • 1. Hydroxychloroquine in COVID-19 Patients: Pros and Cons.
    Younis NK; Zareef RO; Al Hassan SN; Bitar F; Eid AH; Arabi M
    Front Pharmacol; 2020; 11():597985. PubMed ID: 33364965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin.
    Fatima U; Rizvi SSA; Fatima S; Hassan MI
    J Interferon Cytokine Res; 2020 Oct; 40(10):469-471. PubMed ID: 32881593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.
    Naghipour S; Ghodousi M; Rahsepar S; Elyasi S
    Expert Rev Anti Infect Ther; 2020 Nov; 18(11):1119-1133. PubMed ID: 32631083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review.
    Rodrigo C; Fernando SD; Rajapakse S
    Clin Microbiol Infect; 2020 Aug; 26(8):979-987. PubMed ID: 32470568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
    Nina PB; Dash AP
    Indian J Public Health; 2020 Jun; 64(Supplement):S125-S127. PubMed ID: 32496241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review.
    Acharya Y; Sayed A
    Ther Adv Infect Dis; 2020; 7():2049936120947517. PubMed ID: 32821381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.
    Martinez GP; Zabaleta ME; Di Giulio C; Charris JE; Mijares MR
    Curr Pharm Des; 2020; 26(35):4467-4485. PubMed ID: 32634079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 Pneumonia during Hydroxychloroquine Treatment of Rheumatoid Arthritis.
    Gürsoy C; Tapan ÖO; Dogan E; Togan T; Demirbilek SG
    J Coll Physicians Surg Pak; 2020 Oct; 30(10):168-170. PubMed ID: 33291197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hydroxychloroquine and chloroquine for COVID-19: no evidence of effectiveness].
    Vollaard A; Gieling EM; van der Linden PD; Sinha B; de Boer MGJ
    Ned Tijdschr Geneeskd; 2020 Jun; 164():. PubMed ID: 32749808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Waiting for Godot: A cross sectional survey based analysis of the hydroxychloroquine prophylaxis strategy against COVID-19 in India.
    Moni M; Madathil T; Palabatla R; Balachandran S; Edathadathil F; Gutjahr G; Madathil SB; Pai R; Kv B; Jayant A; Sathyapalan DT
    J Public Health Res; 2020 Oct; 9(4):1888. PubMed ID: 33457350
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular Considerations of Experimental Hydroxychloroquine Therapy on Patients Diagnosed With COVID-19: A Case Series Review.
    Patel J; Patel R; Rodriguez LM; Blanco A; Hamza A
    Cureus; 2020 Jul; 12(7):e9151. PubMed ID: 32789088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings.
    Kalra RS; Tomar D; Meena AS; Kandimalla R
    Pathogens; 2020 Jul; 9(7):. PubMed ID: 32645974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis.
    Hong TS; Gonzalez J; Nahass RG; Brunetti L
    Pharmacy (Basel); 2020 Nov; 8(4):. PubMed ID: 33167571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and Hydroxychloroquine.
    Richard SA; Kampo S; Hechavarria ME; Sackey M; Buunaaim ADB; Kuugbee ED; Anabah TW
    J Immunol Res; 2020; 2020():4582612. PubMed ID: 33062720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chloroquine and Hydroxychloroquine: Efficacy in the Treatment of the COVID-19.
    Ho TC; Wang YH; Chen YL; Tsai WC; Lee CH; Chuang KP; Chen YA; Yuan CH; Ho SY; Yang MH; Tyan YC
    Pathogens; 2021 Feb; 10(2):. PubMed ID: 33671315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19, hydroxychloroquine and the importance of disease progression.
    Budny JA
    Toxicol Res (Camb); 2021 Mar; 10(2):299-311. PubMed ID: 34183901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Old drugs for a new indication: a review of chloroquine and analogue in COVID-19 treatment.
    Ehianeta TS; Akinyeye RO; Orege JI; Ejeromedoghene O; Adebule AP; Okonkwo BO
    Porto Biomed J; 2021; 6(3):e132. PubMed ID: 34136717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic status of hydroxychloroquine in COVID-19: A review.
    Kaur K; Kaushal S; Kaushal IG
    J Anaesthesiol Clin Pharmacol; 2020 Aug; 36(Suppl 1):S160-S165. PubMed ID: 33100674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspirin in COVID-19: Pros and Cons.
    Zareef R; Diab M; Al Saleh T; Makarem A; Younis NK; Bitar F; Arabi M
    Front Pharmacol; 2022; 13():849628. PubMed ID: 35370686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.